Publications by authors named "P S Lum"
Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited.
View Article and Find Full Text PDFThe objective was to determine whether gravity support for the left arm of right-handed participants would increase left arm use during a three-dimensional (3-D) reaching task in virtual reality. Twelve healthy control participants each completed 630 reaching movements broken into six blocks. The majority of targets were placed close to the midsagittal plane at three heights, and participants were free to use either limb when reaching for targets.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers assessed pain severity before and after treatment with sofosbuvir/velpatasvir, mainly focusing on whether achieving sustained virologic response (SVR) correlated with lower pain scores.
- * Results showed that while overall pain severity didn't significantly differ based on SVR status, those who achieved SVR reported lower pain scores over time, especially among participants with moderate or greater pain at baseline, except at the 48-week mark for those who did not achieve SVR.
Heterogeneity of outcomes across different clinical trial study sites is often inevitable. Understanding how outcomes differ by site is important for planning future programs and studies. We examined the extent of heterogeneity of hepatitis C virus (HCV) treatment cascade outcomes among persons who inject drugs (PWIDs) across sixteen clinical sites utilized in the HERO Study-a pragmatic randomized trial of HCV treatment support.
View Article and Find Full Text PDFImportance: Hepatitis C virus (HCV) reinfection after curative treatment remains a concern for people who inject drugs.
Objective: To assess the incidence of HCV reinfection and associated risk factors.
Design, Setting, And Participants: This cohort study is a secondary analysis of a randomized clinical trial that was conducted across opioid treatment programs and community health centers in the US between September 2016 and August 2018.